Search Antibody Database

Found 1 matching record:

Displaying record number 2895

Download this epitope record as JSON.

MAb ID	CH23
HXB2 Location	gp160(302-318) DNA(7128..7178)	gp160 Epitope Map
Author Location	gp120
Epitope	NTRTSINIGPGQVFY	Epitope Alignment
Subtype	B, CRF01_AE
Ab Type	gp120 V3 // V3 glycan (V3g)
Neutralizing	yes
Species (Isotype)	human(IgG1)
Patient	T143859
Immunogen	vaccine
Country	Thailand
Keywords	ADCC, antibody binding site, antibody generation, antibody sequence, glycosylation, review, vaccine antigen design, vaccine-induced immune responses

Notes

Showing 4 of 4 notes.

• CH23: This study describes the generation of CHO cell lines stably expressing the following vaccine Env Ags: CRF01_AE A244 Env gp120 protein (A244.AE) and 6240 Env gp120 protein (6240.B). The antigenic profiles of the molecules were assessed with a panel of well-characterized mAbs recognizing critical epitopes and glycosylation analysis confirming previously identified sites and revealing unknown sites at non-consensus motifs. A244.AE gp120 bound to CH23 in ELISA EC50 and Surface Plasmon Resonance (SPR) assays. Wen2018 (glycosylation, vaccine antigen design)
• CH23: 23 ADCC-mediating MAbs induced by AVAC-HIV/AIDSVAX B/E vacine were isolated from 6 vaccine recipients. All donors had negative serology for HIV-1. The MAbs were modestly somatically mutated and preferentially used VH1 gene segment. 19 MAbs, including MAb CH23, were directed against conformational MAb A32-blockable gp120 epitopes. MAb CH23 was isolated from Subject T143859. Bonsignori2012a (ADCC, antibody generation, antibody sequence)
• CH23: The complexity of the epitopes recognized by ADCC responses in HIV-1 infected individuals and candidate vaccine recipients is discussed in this review. CH23, generated by a vaccine recipient of phase II RV135 clinical trial, is discussed as the V3 region-targeting, neutralizing anti-gp120 mAb exhibiting ADCC activity and having a linear epitope. Pollara2013 (ADCC, review)
• CH23: NAb response was compared in 2 HIV-1 vaccine efficacy trials in which either partial protection (RV144) or no protection (Vax003) was seen. The peak NAb response in RV144 was substantially weaker than the peak response in Vax003, suggesting that either weak neutralizing antibody responses can be partially protective in low-risk heterosexual populations or that the modest efficacy seen in RV144 was mediated by other immune responses. MAb CH23 was vaccine-induced antibody, isolated from subject T143859 in RV144 trial. CH23 used V-gene segment, had no detectable neutralizing activity against tier 2 viruses, but showed a strong preference for TH023.6 (CRF01_AE), and mapped to V3 linear peptide NTRTSINIGPGQVFY. Montefiori2012 (antibody binding site, antibody generation, vaccine-induced immune responses)

References

Showing 4 of 4 references.

Isolation Paper
Montefiori2012 David C. Montefiori, Chitraporn Karnasuta, Ying Huang, Hasan Ahmed, Peter Gilbert, Mark S. de Souza, Robert McLinden, Sodsai Tovanabutra, Agnes Laurence-Chenine, Eric Sanders-Buell, M. Anthony Moody, Mattia Bonsignori, Christina Ochsenbauer, John Kappes, Haili Tang, Kelli Greene, Hongmei Gao, Celia C. LaBranche, Charla Andrews, Victoria R. Polonis, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Steve G. Self, Phillip W. Berman, Donald Francis, Faruk Sinangil, Carter Lee, Jim Tartaglia, Merlin L. Robb, Barton F. Haynes, Nelson L. Michael, and Jerome H. Kim. Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. J. Infect. Dis., 206(3):431-441, 1 Aug 2012. PubMed ID: 22634875. Show all entries for this paper.

Bonsignori2012a Mattia Bonsignori, Justin Pollara, M. Anthony Moody, Michael D. Alpert, Xi Chen, Kwan-Ki Hwang, Peter B. Gilbert, Ying Huang, Thaddeus C. Gurley, Daniel M. Kozink, Dawn J. Marshall, John F. Whitesides, Chun-Yen Tsao, Jaranit Kaewkungwal, Sorachai Nitayaphan, Punnee Pitisuttithum, Supachai Rerks-Ngarm, Jerome H. Kim, Nelson L. Michael, Georgia D. Tomaras, David C. Montefiori, George K. Lewis, Anthony DeVico, David T. Evans, Guido Ferrari, Hua-Xin Liao, and Barton F. Haynes. Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. J. Virol., 86(21):11521-11532, Nov 2012. PubMed ID: 22896626. Show all entries for this paper.

Pollara2013 Justin Pollara, Mattia Bonsignori, M. Anthony Moody, Marzena Pazgier, Barton F. Haynes, and Guido Ferrari. Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity (ADCC) Responses. Curr. HIV Res., 11(5):378-387, Jul 2013. PubMed ID: 24191939. Show all entries for this paper.

Wen2018 Yingxia Wen, Hung V. Trinh, Christine E Linton, Chiara Tani, Nathalie Norais, DeeAnn Martinez-Guzman, Priyanka Ramesh, Yide Sun, Frank Situ, Selen Karaca-Griffin, Christopher Hamlin, Sayali Onkar, Sai Tian, Susan Hilt, Padma Malyala, Rushit Lodaya, Ning Li, Gillis Otten, Giuseppe Palladino, Kristian Friedrich, Yukti Aggarwal, Celia LaBranche, Ryan Duffy, Xiaoying Shen, Georgia D. Tomaras, David C. Montefiori, William Fulp, Raphael Gottardo, Brian Burke, Jeffrey B. Ulmer, Susan Zolla-Pazner, Hua-Xin Liao, Barton F. Haynes, Nelson L. Michael, Jerome H. Kim, Mangala Rao, Robert J. O'Connell, Andrea Carfi, and Susan W. Barnett. Generation and Characterization of a Bivalent Protein Boost for Future Clinical Trials: HIV-1 Subtypes CR01\_AE and B gp120 Antigens with a Potent Adjuvant. PLoS One, 13(4):e0194266, 2018. PubMed ID: 29698406. Show all entries for this paper.